Hormonal
Obesity increases the risk of kidney stones (nephrolithiasis) and kidney cancer through mechanisms involving insulin resistance, acidic urine, and adipose-derived inflammatory factors.
If you are overweight, you are at higher risk for kidney stones and kidney cancer. This is partly due to how your body processes acids and minerals. Staying well-hydrated and maintaining a healthy weight through balanced eating can help reduce these risks. Be cautious with extreme weight loss methods, as they can sometimes increase stone risk.
Obesity is associated with a number of risk factors contributing to the higher incidence and prevalence of nephrolithiasis. Higher body weight is associated with lower urine pH and increased urinary oxalate, uric acid, sodium and phosphate excretion. The insulin resistance characteristic of obesity may also predispose to nephrolithiasis through its impact on tubular Na–H exchangers and ammoniagenesis, and the promotion of an acidic milieu.
Why this rating
Supported by multiple population-based studies and meta-analyses cited in the review.
Source
Obesity and kidney disease: hidden consequences of the epidemic
Csaba P. Kövesdy et al. · Journal of Endocrinology Metabolism and Diabetes of South Africa · 2017
DOI 10.1080/16089677.2017.1299975
More from this paper
- High body mass index (BMI) is a strong independent risk factor for the development and progression of chronic kidney disease (CKD), primarily driven by compensatory glomerular hyperfiltration and increased intraglomerular pressure.Good
- Weight loss interventions, including lifestyle changes and ACE inhibition, can reduce blood pressure, glomerular hyperfiltration, and proteinuria in obese patients with CKD.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →